Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results.

MLA

Garon, E. B., et al. “Ramucirumab plus Erlotinib versus Placebo plus Erlotinib in Previously Untreated EGFR-Mutated Metastatic Non-Small-Cell Lung Cancer (RELAY): Exploratory Analysis of next-Generation Sequencing Results.” ESMO Open, vol. 8, no. 4, Aug. 2023, p. 101580. EBSCOhost, https://doi.org/10.1016/j.esmoop.2023.101580.

APA

Garon, E. B., Reck, M., Nishio, K., Heymach, J. V., Nishio, M., Novello, S., Paz-Ares, L., Popat, S., Aix, S. P., Graham, H., Butts, B. D., Visseren-Grul, C., & Nakagawa, K. (2023). Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results. ESMO Open, 8(4), 101580. https://doi.org/10.1016/j.esmoop.2023.101580

Chicago

Garon, E B, M Reck, K Nishio, J V Heymach, M Nishio, S Novello, L Paz-Ares, et al. 2023. “Ramucirumab plus Erlotinib versus Placebo plus Erlotinib in Previously Untreated EGFR-Mutated Metastatic Non-Small-Cell Lung Cancer (RELAY): Exploratory Analysis of next-Generation Sequencing Results.” ESMO Open 8 (4): 101580. doi:10.1016/j.esmoop.2023.101580.